nalmefene prodrug (NRS-033) / Nirsum Labs - LARVOL DELTA

Single Ascending Dose Study of NRS 033 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Nirsum Labs | Active, not recruiting ➔ Completed

Trial completion

Single Ascending Dose Study of NRS 033 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Nirsum Labs | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2024 ➔ Sep 2024 | Trial primary completion date: Jun 2024 ➔ Sep 2024

Enrollment closed • Trial completion date • Trial primary completion date

Single Ascending Dose Study of NRS 033 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Nirsum Labs | Trial completion date: Mar 2024 ➔ Jun 2024 | Trial primary completion date: Mar 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date

Single Ascending Dose Study of NRS 033 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Nirsum Labs | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2023 ➔ Mar 2024 | Trial primary completion date: Nov 2023 ➔ Mar 2024

Enrollment open • Trial completion date • Trial primary completion date